IRIS
BOCCUTO, ADELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.952
EU - Europa 2.640
AS - Asia 1.058
SA - Sud America 225
Continente sconosciuto - Info sul continente non disponibili 140
AF - Africa 72
OC - Oceania 4
Totale 7.091
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.867
RU - Federazione Russa 613
IT - Italia 561
GB - Regno Unito 485
SG - Singapore 323
IE - Irlanda 307
CN - Cina 258
BR - Brasile 189
SE - Svezia 168
DE - Germania 138
FR - Francia 137
HK - Hong Kong 120
VN - Vietnam 111
IN - India 70
FI - Finlandia 55
UA - Ucraina 47
ES - Italia 35
ZA - Sudafrica 35
CA - Canada 34
BD - Bangladesh 28
KR - Corea 28
JP - Giappone 24
TR - Turchia 23
MX - Messico 19
BE - Belgio 16
PL - Polonia 15
NG - Nigeria 13
NL - Olanda 13
AR - Argentina 12
MA - Marocco 10
UZ - Uzbekistan 10
IQ - Iraq 9
IR - Iran 9
AT - Austria 7
CO - Colombia 6
CZ - Repubblica Ceca 6
GP - Guadalupe 6
GR - Grecia 6
ID - Indonesia 6
JM - Giamaica 6
TT - Trinidad e Tobago 6
EC - Ecuador 5
PK - Pakistan 5
DK - Danimarca 4
EG - Egitto 4
GT - Guatemala 4
LV - Lettonia 4
PT - Portogallo 4
PY - Paraguay 4
RO - Romania 4
CI - Costa d'Avorio 3
CR - Costa Rica 3
HN - Honduras 3
IL - Israele 3
JO - Giordania 3
RS - Serbia 3
TH - Thailandia 3
TW - Taiwan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
CH - Svizzera 2
CL - Cile 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
EE - Estonia 2
ET - Etiopia 2
KE - Kenya 2
LT - Lituania 2
LU - Lussemburgo 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
UY - Uruguay 2
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EU - Europa 1
GE - Georgia 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
ML - Mali 1
MN - Mongolia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
TN - Tunisia 1
Totale 6.954
Salva come PNG Salva come JPEG
Città #
Southend 410
Dallas 304
Dublin 303
Fairfield 221
Ashburn 210
San Jose 205
Chandler 198
Moscow 179
Singapore 175
Santa Clara 159
Hong Kong 111
Siena 111
Milan 110
Beijing 102
Seattle 84
Woodbridge 80
Council Bluffs 73
Houston 73
Ann Arbor 71
Cambridge 71
Rome 62
Wilmington 61
Los Angeles 56
New York 56
Princeton 54
Munich 52
Ho Chi Minh City 45
Lauterbourg 41
Jacksonville 40
Johannesburg 34
Helsinki 33
Hefei 29
The Dalles 29
Seoul 25
Boardman 24
São Paulo 24
Málaga 22
Bengaluru 21
Tokyo 20
Hanoi 18
Portsmouth 17
San Diego 17
Brussels 16
San Mateo 16
Frankfurt am Main 15
Buffalo 14
Orem 14
Shanghai 14
Abuja 13
London 13
Redondo Beach 13
Dearborn 12
Montreal 12
Brooklyn 11
Columbus 11
Florence 11
North Bergen 11
Warsaw 11
Brescia 10
Düsseldorf 10
Lappeenranta 10
Redwood City 10
Atlanta 9
Figino 9
Fremont 9
Manchester 9
Mexico City 9
Naples 9
Nuremberg 9
Turku 9
Nanjing 8
Phoenix 8
Toronto 8
Chennai 7
Dong Ket 7
Izmir 7
Paris 7
Rio de Janeiro 7
Roccagorga 7
Tashkent 7
Belo Horizonte 6
Brasília 6
Denver 6
Indianapolis 6
Mumbai 6
Tucson 6
Vienna 6
Andover 5
Haiphong 5
Perugia 5
San Francisco 5
Zanjan 5
Amsterdam 4
Bangalore 4
Barnet 4
Cagliari 4
Cairo 4
Chaguanas 4
Changsha 4
Charlotte 4
Totale 4.521
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 343
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 320
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 315
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 311
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 311
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 277
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 271
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 265
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 265
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 263
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 253
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 238
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 236
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 231
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 221
Novel antiviral strategies against emerging viral diseases 216
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 204
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 202
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 198
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 194
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 172
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 158
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 157
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 155
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 155
Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis 154
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 152
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 147
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 143
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 143
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 130
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 124
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 77
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 58
null 32
Totale 7.091
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022533 0 0 0 88 43 46 43 47 34 57 61 114
2022/2023613 41 98 71 60 46 103 32 38 49 34 25 16
2023/2024521 18 17 48 31 5 147 168 10 0 15 12 50
2024/20251.087 28 40 157 51 110 77 41 90 113 69 110 201
2025/20262.521 150 293 249 348 547 86 256 79 86 159 80 188
2026/2027423 85 53 143 142 0 0 0 0 0 0 0 0
Totale 7.091